Moreover, in EGFR-driven lung cancer and CRC, MET activation is a very common cause of resistance to anti-EGFR drugs [14,15,20,62], so that the use of MET inhibitors could possibly overcome this resistance. The gene discussed is MET; the disease is lung carcinoma.